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San Francisco Medical Center as a prospective image-based outcome study. All patients with suspected acute ischemic stroke who presented within 24 hours of symptom onset and had multimodal CT examination (ie, unenhanced head CT and arch-to-vertex head and neck CTA) were consented for data collection and 6-month followup. Exclusion criteria included intracranial hemorrhage, contraindication to iodinated contrast agent, and having a stroke while in hospital. During the study period, all patients with suspected stroke or transient ischemic attack had multimodal CT examination as part of their routine clinical care in both institutions, except those with a contraindication to intravenous contrast. Surrogate consent was obtained when the patient was unable to communicate. The study received Institutional Review Board approval from both institutions and was Health Insurance Portability and Accountability Act compliant.
Patients were managed according to our routine clinical workflow, which specifies that the decision to treat with IV-tPA be made immediately at the time of CT scanning, before the CTA acquisition. Contraindications to IV-tPA included any hemorrhage on CT and last known normal >3 hours; large CT hypodensity (more than one third middle cerebral artery territory) was considered a relative contraindication.
Demographic data, past medical history, and National Institutes of Health stroke scale (NIHSS) scores were obtained at admission. Modified Rankin scale (mRS) scores were obtained at 6 months. [4] [5] [6] Favorable outcome was defined as mRS≤2, and poor outcome as mRS>2. Patients were excluded if reliable mRS or NIHSS scores were not obtained. Study staff certified by the NIHSS training program of the American Stroke Association obtained the mRS and NIHSS scores. 
Scanning Procedures
Noncontrast computed tomography and arch-to-vertex CTA were performed according to standard protocols with multidetector CT scanners (LightSpeed; GE Healthcare, Chalfont St. Giles, UK). 8 Representative noncontrast computed tomography parameters were the following: 120 to 140 kVp, 170 mA, 2-second scan time, and 5-mm section thickness. Biphasic helical CTA scanning, at the same head tilt, was performed immediately afterward, with 100 to 140 mL of contrast (Isovue; Bracco Diagnostics, Princeton, NJ) at 3 mL/s and a 25-second delay (40 seconds for patients in atrial fibrillation). Parameters were 140 kVp, 220 to 250 mA, 0.8 to 1.0-second rotation, 2.5-mm section thickness, 1.25-mm reconstruction interval, 3.75-mm/rotation table speed, and 0.75:1 pitch. Source images were reconstructed into standardized maximum intensity projections of the intracranial and extracranial vasculature.
Image Review
Image review was independently performed on a workstation (Impax; Agfa Technical Imaging Systems, Richfield Park, NJ) by neuroradiologists or neurologists (M.H.L., E.C., and W.J.K.) as previously described. 9 Reviewers had information on patient age, sex, and presenting clinical symptoms but were blinded to all information after the initial emergency evaluation. 10 Noncontrast computed tomography images were reviewed first, followed by CTA. Disagreements were resolved by consensus. The reviewers recorded both major intracranial arterial occlusions and brain areas with hypodensity considered to have resulted from acute ischemia. A major anterior circulation occlusion was defined as occlusion of the terminal internal carotid artery and proximal middle cerebral artery (M1, M2) segments.
Statistical Analysis
Comparisons were tested for statistical significance using χ 2 2×4 contingency tables, Fisher exact tests, or t tests, as appropriate, with significance defined as P≤0.05 (all P values 2-tailed unless noted otherwise). Multivariate binary logistic regression, both with and without stepwise-forward likelihood ratio variable entry, was performed by using dichotomized outcome (mRS>2 poor versus mRS≤2 good). Input variables, adjusted for time-to-CTA by forced entry, included admission NIHSS, major vessel occlusion, IV-tPA therapy, and the interaction terms between NIHSS×tPA and occlusion×tPA. All statistical results were calculated using SPSS (SPSS Inc, version 20.0, Chicago, IL).
Results
A total of 742 patients were enrolled in STOPStroke; in which, 90 patients were excluded for lack of a reliable mRS at 6 months, and 3 patients were excluded for lack of reliable NIHSS scores at admission. Thus, 649 patients formed the analyzed cohort and, of these, 101 patients (15.6%) received IV-tPA within 3 hours of stroke onset (86 patients received IV-tPA only, and 15 patients received both IV-tPA and endovascular therapy). For all patients who received IV-tPA, mean time from symptom onset to administration was 124.5±37.1 (SD) minutes. In patients with NIHSS>10 who received IV-tPA (n=64/188), mean time from symptom onset to administration was 126.5±36.1 (SD) minutes. The majority of patients who did not receive IV-tPA (≈80%, 125 out of 158 patients) were imaged beyond the 3-hour time window for thrombolysis. Tables 1 and 2 show patient demographics, comorbidities, and endovascular (intra-arterial) treatment of both the entire (Table 1 ) and NIHSS>10 (Table 2) cohorts, stratified by IV-tPA treatment. Of the 101 patients who received IV-tPA, 50 patients had good outcomes (50/101, 50%). This good outcome rate was significantly lower than that of the 346 out of 548 (63%) similar patients who did not receive IV-tPA (P=0.010). However, 342 of these untreated patients had mild clinical symptoms (NIHSS≤5) as compared with 10 in the IV-tPA-treated group. If these subsets were removed, there were better outcomes in those receiving (43/91, 47%) versus not receiving IV-tPA (70/206, 34%; P=0.04).
Multivariate binary logistic stepwise-forward regression modeling was performed on the entire STOPStroke cohort, both including (n=649) and excluding (n=618) patients who received endovascular-only treatment. In the model with forward regression and interaction terms, for both groups, only (1) admission NIHSS and (2) the interaction term between major vessel occlusion and IV-tPA therapy were significant (P<0.001), supporting that the effects of IV-tPA on outcome vary with the presence or absence of major vessel occlusion. In the binary logistic model without forward regression or interaction terms entered, NIHSS, occlusion, and IV-tPA were all highly significant outcome predictors (P<0.004). When time-to-CTA was adjusted for by forced entry into the models, these results were unchanged.
The effect of IV-tPA on good outcome rates for the entire STOPStroke cohort, stratified by admission NIHSS score, is shown in Table 3 . For patients with admission NIHSS>5 treated with IV-tPA, the reduction of risk for poor outcome was similar for each of the different subgroups shown in Table 3 (the number needed to harm in the NIHSS≤5 group was 10 [95% confidence interval, −18% to 39%; P=NS]). The 2 groups of patients that most strongly benefitted from IV-tPA were those with (1) NIHSS of 6 to 10, and (2) NIHSS>10 with major anterior occlusion documented by CTA. Stratification by occlusion did not significantly change the results for the NIHSS 6 to 10 group. The numbers needed to treat in these 2 classes were 5 (95% confidence interval, 2-53) and 7 (95% confidence interval, 3-60), respectively.
A beneficial effect of IV-tPA treatment in patients presenting with severe neurological symptoms (NIHSS>10) is observed when patients are stratified by the presence of a major anterior circulation occlusion. χ 2 2×4 contingency table analysis of good versus poor outcomes in patients with NIHSS>10 without posterior circulation involvement (n=175, with/without occlusion and with/without IV-tPA administration) disclosed highly significant differences (P<0.001). Patients with NIHSS>10 with major anterior circulation occlusions who received IV-tPA had significantly better outcomes (17/49, 35%) than similar patients who did not receive IV-tPA (13/77, 17%; P=0.031). Although there was a trend toward better outcomes in patients with NIHSS>10 without major occlusions who received IV-tPA (6/13, 46%) compared with those who did not receive IV-tPA (11/36, 31%), this did not reach significance (P=0.331), likely because of the small cohort size.
These results were essentially identical when the entire cohort of patients with NIHSS>10, including those with both posterior fossa involvement (n=13) and endovascular treatment (n=29), were analyzed (Table 2 ). In this cohort (n=188), the good outcome rate for those with occlusion was 33% (17 out of 51 patients) IV-treated versus 17% (14 out of 84 patients; P=0.034) non-IV-treated, compared with 46% (6 out of 13 patients) IV-treated versus 33% (13 out of 40 patients; P=0.507) non-IV-treated for those without occlusion. These percentage-good outcome rates were similarly unchanged when the patients with anterior circulation stroke with endovascular treatment were excluded (n=151; 104 with occlusion; P=0.07 1-sided). Moreover, when patients with admission CT Alberta Stroke Program Early Computed Tomography Score (ASPECTS)≤7 were excluded from the full NIHSS>10 cohort (ie, excluding patients with a relative contraindication to IV-lytic therapy based on admission hypodensity lesion size), the proportion of good outcomes for those with occlusion was 40% treated versus 17% untreated (P=0.05), compared with 50% treated versus 33% untreated (P=0.50) for those without occlusion.
Discussion
Outcomes of patients with ischemic stroke with documented cerebral artery occlusions treated with IV-tPA are not well studied and are poorly understood. The imperative to treat promptly supersedes other considerations, and imaging for vascular occlusion is typically not performed. Patients in the STOPStroke study were unusual in that they underwent CTA as part of their initial stroke evaluation after the decision to administer IV-tPA based on the unenhanced CT findings, and these data have revealed new information on the efficacy of IV-tPA. Most importantly, the STOPStroke study indicates that in patients presenting with (15) 15 (12) 14 (22) 0.112
Post fossa, n (%) 13 (7) 11 (9) 2 (3) severe stroke symptoms caused by major anterior circulation artery occlusions, IV-tPA improves outcomes with an efficacy comparable with those found in endovascular therapy trials of like cohorts. 11, 12 The >30% good outcome rate produced by IV-tPA is a threshold that is considered successful for endovascular therapy. Indeed, according to recent benchmarks agreed on by 8 professional societies, "intra-arterial treatment for stroke should … result in a good outcome in ≥30% of patients." 13 Notably, this benefit was found to be statistically significant in a small number of patients: 49 with NIHSS>10 and anterior circulation occlusions received IV-tPA, whereas 77 did not receive the thrombolytic therapy.
The data presented here are congruent with the large number of research studies on the clinical use of IV-tPA.
14 The findings also help illuminate the results of the Interventional Management of Stroke III trial (IMS III), 15 which was a phase III, randomized, multicenter, open label, 900-subject clinical trial that examined whether a combined intravenous and endovascular approach to recanalization is superior to standard IV-tPA alone when initiated within 3 hours of acute ischemic stroke onset. On the recommendation of the Data and Safety Monitoring Board, enrollment was stopped because the data collected showed no difference in proportion with good clinical outcome for those patients treated with IV-tPA alone versus those treated with IV-tPA plus intra-arterial therapy (38.7% versus 40.8%, respectively). An uncertainty in the IMS III trial was that arterial occlusion status in the IV-tPA-only treated group was not documented.
The efficacy of IV-tPA in patients with major anterior circulation occlusion that we observed in the STOPStroke cohort is also in line with the results of the Local Versus Systemic Thrombolysis for Acute Ischemic Stroke (SYNTHESIS) trial in which the clinical efficacy of endovascular treatment was compared with that of IV-tPA treatment. 16 It was reported that at 3 months, 30.4% of endovascular therapy group and 34.8% of the IV-tPA group were alive without disability. The SYNTHESIS trial also did not document arterial occlusion in the IV-tPA group. Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE) is a third major trial in which IV-tPA was compared with endovascular therapy. 17 Again, the 3-month post-treatment outcomes of patients with severe ischemic stroke were not significantly different between patients who received IV-tPA and those who were treated endovascularly; of note, arterial occlusions were documented in all treated patients.
The other major finding in this study is confirmation of the observation by Ingall et al that patients with moderate symptoms (NIHSS 6-10) are most likely to benefit from IV-tPA. 18 Approximately half of all patients with moderate symptoms in STOPStroke have good outcomes without treatment; however, ≈75% of such patients have good outcomes if they are given IV-tPA. What is new is that only a minority (29%, 32/109) of these patients had occlusions identifiable by CTA, yet IV-tPA was still highly beneficial. A likely explanation is that patients with moderate symptoms are more likely to have CTAundetected distal branch occlusions that are readily amenable to lysis by IV-tPA. Good outcomes in patients with occlusions on CTA were much less common, even if treated with IV-tPA, emphasizing the need for improved treatments for this group.
Patients in STOPStroke were recruited prospectively without regard to anterior or posterior circulation symptoms, and image analysis was performed blinded to the clinical CTA reports or outcomes. Although the possibility of selection bias exists because CTA was performed for specific clinical presentations, the potential for such bias was limited by the fact that STOPStroke enrollment required all patients with acute ischemic symptoms to undergo noncontrast computed tomography followed by CTA, regardless of symptom severity, unless specifically contraindicated. It is also noteworthy that despite the observational nature of our study and lack of randomization, differences in outcome between the treated and untreated groups are unlikely to be biased by the presence or absence of large vessel occlusion because the decision to administer IV-tPA was made immediately after the unenhanced CT before and independent of the CTA results. Moreover, because admission infarct size is another possible source of bias, we performed a subgroup analysis excluding patients with low admission ASPECTS scores (≤7), which resulted in similar good outcome rates as our primary analysis.
There are other potential limitations to our study. The confidence intervals for the number needed to treat and number needed to harm analyses are wide and underpowered. Also, data are unavailable concerning the number and specific reasons for nonenrollment, although our ability to obtain surrogate consent may have, in part, mitigated any potential bias toward enrolling less severe strokes. Indeed, although our cohort was treated before European Cooperative Acute Stroke Study III (ECASS III), standardization of statins in acute stroke management, and widespread acceptance of the more aggressive use of IV-tPA in patients with relative contraindications, it is striking that our percentage of good outcomes, even in patients who Table 3 . Effect of IV-tPA on Good Outcome rates (n, %) in the Entire STOPStroke Cohort, Stratified by Admission NIHSS score were severely symptomatic (NIHSS>10), were IV-tPA-treated, and had large vessel occlusion, so closely matches that of more recent trials of both IV and intra-arterial therapy in similarly symptomatic patients. 11, 12 The value of IV-tPA in such severely symptomatic patients with CTA proven large vessel occlusion has not been previously been emphasized.
In summary, STOPStroke has revealed that treatment with IV-tPA results in better outcomes in patients with severe stroke symptoms with major anterior circulation occlusions than in similar patients that did not receive IV-tPA. Treatment using targeted vascular imaging such as CTA may be important for patient selection and stratification in clinical trials of ischemic stroke, including direct comparisons between IV-thrombolytic and endovascular approaches.
